CAPR
Capricor Therapeutics Inc
stockNASDAQ
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor's lead candidate, cap-1002, is an "off-the-shelf" cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system's activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 8.71 | 2026-09-28 | +2.93% | -5.516 |
| 1M | 9.40 | 2026-09-04 | -4.63% | 1.667 |
| 3M | 22.43 | 2026-07-06 | -60.03% | -1.065 |
| 6M | 31.68 | 2026-04-06 | -71.70% | -0.544 |
| 1Y | 7.81 | 2025-10-06 | +14.79% | -0.752 |
| 2Y | 21.65 | 2024-10-04 | -58.59% | — |
| 5Y | 3.84 | 2021-10-05 | +133.46% | -0.328 |
Capricor Therapeutics Inc (NASDAQ:CAPR) stock price today is $8.97, and today's volume is 2,638,977. CAPR is up 0.280% today. The 30 day average volume is 5.58M. CAPR market cap is $521.22M with 58.14M shares outstanding.